Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) may arise from genomic instability and has dismal outcome. Sorafenib is the first-line treatment for advanced stage HCC, but its therapeutic efficacy is less than 50%. Biomarkers for predicting the therapeutic efficacy of sorafenib administration to patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ming-Chin, Wu, Tsung-Han, Lee, Chao-Wei, Lee, Yun-Shien, Lian, Jang-Hau, Tsai, Chia-Lung, Hsieh, Sen-Yung, Tsai, Chi-Neu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chang Gung University 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038951/
https://www.ncbi.nlm.nih.gov/pubmed/35747997
http://dx.doi.org/10.1016/j.bj.2020.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038951/
https://www.ncbi.nlm.nih.gov/pubmed/35747997
http://dx.doi.org/10.1016/j.bj.2020.07.001

Ejemplares similares